TY - BOOK
TI - Pharmacoepigenetics of Histone Deacetylase Inhibitors in Cancer
AU - Garmpis, N.
AU - Damaskos, C.
AU - Garmpi, A.
AU - Valsami, S.
AU - Dimitroulis, D.
PB - Elsevier
PY - 2019
CY - 
SN - 9780128139394
TODO - 10.1016/B978-0-12-813939-4.00013-9
TODO - null
TODO - Histone modification, which occurs through the process of acetylation, plays a key role in the epigenetic regulation of gene expression. The balance between histone deacetylases (HDACs) and histone acetyltransferases controls this process. HDAC inhibitors (HDACi) can induce cancer cell cycle arrest, differentiation, and cell death, reduce angiogenesis, and modulate immune response. Therefore, HDACi represent a group of enzymes that can be used for the development of pharmaceutical agents against a variety of malignant neoplastic diseases. The mechanisms behind HDACi anticancer effects depend on many factors. The HDACi vorinostat, romidepsin, and belinostat have been approved for some T cell lymphomas and panobinostat for multiple myeloma. Other HDACi are in clinical trials for the treatment of hematological and solid malignancies. The results of such studies are promising but further studies on a greater scale are needed. © 2019 Elsevier Inc. All rights reserved.
ER -